Libo Pharma Corp. (TPEX:7888)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
43.15
-0.30 (-0.69%)
At close: Apr 17, 2026
Market Cap3.25B
Revenue (ttm)n/a
Net Income-296.30M
EPS-4.74
Shares Out75.24M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume30,903
Average Volume41,771
Open43.45
Previous Close43.45
Day's Range42.85 - 43.45
52-Week Range40.55 - 69.00
Betan/a
RSI38.94
Earnings DateJun 18, 2026

About Libo Pharma

Libo Pharma Corp., a clinical-stage biopharmaceutical company, engage in novel therapeutics development in the field of oncology and hematology. The company offers LIB-101, an interleukin-12 (IL-12) cytokine immunotherapy for innate immunity, adaptive immunity, and hematopoiesis. Libo Pharma Corp. was founded in 2017 and is based in Taipei, Taiwan. [Read more]

Industry Pharmaceutical Preparations
Founded 2017
Employees 31
Stock Exchange Taipei Exchange
Ticker Symbol 7888
Full Company Profile

Financial Performance

Financial Statements